Circulating Complex of Lipoprotein(a) and Proprotein Convertase Subtilisin/Kexin Type 9 in the Serum Measured by...

Area of Science:

• Biochemistry
• Cardiovascular Science
• Molecular Biology

Background:

• Lipoprotein(a) (Lp(a)) is a lipoprotein particle implicated in cardiovascular disease risk.
• Proprotein convertase subtilisin/kexin type 9 (PCSK9) is a key regulator of cholesterol metabolism.
• The interaction and complex formation between Lp(a) and PCSK9 in circulation are not well understood.

Purpose of the Study:

• To investigate the presence and characteristics of a circulating complex between Lp(a) and PCSK9.
• To determine if the levels of this complex correlate with individual Lp(a) and PCSK9 concentrations.
• To explore the potential physiological significance of the Lp(a)-PCSK9 complex.

Main Methods:

• Enzyme-linked immunosorbent assay (ELISA) was employed to detect and quantify the Lp(a)-PCSK9 complex.
• Blood samples from healthy volunteers and patients with cardiovascular diseases were analyzed.

Main Results:

• A complex of Lp(a) and PCSK9 was detected in the blood of both healthy individuals and cardiovascular disease patients.
• The levels of the Lp(a)-PCSK9 complex exhibited wide variability.
• Complex levels did not correlate with the independent concentrations of Lp(a) or PCSK9.

Conclusions:

• The Lp(a)-PCSK9 complex is present in circulation across different health statuses.
• The independent levels of Lp(a) and PCSK9 do not predict the abundance of their complex.
• These findings suggest a potential physiological role for lipoprotein(a) as a transporter of PCSK9.